Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial
SKIN The Journal of Cutaneous Medicine · 10.03.2026 · 10 (2) · s744
DOI: 10.25251/ppt8ep84 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.03.2026. Verfasst von Benjamin Ehst und 9 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
N/A
Zitieren
APA
Ehst, B., Warren, R. B., Hong, H. C., Lee, D. H., Metelitsa, A., Volc, S., Tauber, M., Safavimanesh, F., Tindberg, A., & Gold, L. S. (2026). Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial. SKIN The Journal of Cutaneous Medicine, 10(2), s744. https://doi.org/10.25251/ppt8ep84
Vancouver
Ehst B, Warren RB, Hong HC, Lee DH, Metelitsa A, Volc S, et al. Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial. SKIN The Journal of Cutaneous Medicine. 2026;10(2):s744. doi:10.25251/ppt8ep84
BibTeX
@article{Ehst2026,
author = {Ehst, Benjamin and Warren, Richard B and Hong, H. Chih-ho and Lee, Dong Hun and Metelitsa, Andrei and Volc, Sebastian and Tauber, Marie and Safavimanesh, Farzaneh and Tindberg, Ann-Marie and Gold, Linda Stein},
title = {Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {2},
pages = {s744},
doi = {10.25251/ppt8ep84}
}
EUVIMED